FGFR4 antibodies
AssigneeU3 Pharma GmbH
InventorsJohannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe
Life of this patent
Estimating the term…
Abstract
The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.
Claims18
An isolated antibody that binds to the extracellular domain of FGFR4 or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment comprises at least one heavy chain amino acid sequence comprising the following CDRs:
- (a) a CDRH1 as shown in SEQ ID NO:
- 15,
- (b) a CDRH2 as shown in SEQ ID NO:
- 16, and
- (c) a CDRH3 as shown in SEQ ID NO:
- 17, and
- at least one light chain amino acid sequence comprising the following CDRs:
- (d) a CDRL1 as shown in SEQ ID NO:
- 18,
- (e) a CDRL2 as shown in SEQ ID NO:
- 19, and
- (f) a CDRL3 as shown in SEQ ID NO:
- 20.
An isolated antibody that binds to the extracellular domain of FGFR4 or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment comprises at least one heavy chain amino acid sequence comprising the following CDRs:
- (a) a CDRH1 as shown in SEQ ID NO:
- 15,
- (b) a CDRH2 as shown in SEQ ID NO:
- 16, and
- (c) a CDRH3 as shown in SEQ ID NO:
- 17, and
- at least one light chain amino acid sequence comprising the following CDRs:
- (d) a CDRL1 as shown in SEQ ID NO:
- 18,
- (e) a CDRL2 as shown in SEQ ID NO:
- 19, and
- (f) a CDRL3 as shown in SEQ ID NO:
- 20,
- wherein said antibody reduces or blocks FGFR4 phosphorylation by reducing or blocking FGFR4-mediated signal transduction;
- said antibody binds to the extracellular domain of FGFR4 at a location which reduces or blocks ligand binding;
- said antibody inhibits enough FGFR4 activity to reduce or block cell proliferation;
- and said antibody inhibits enough FGFR4 activity to reduce or block cell migration.
Dependencies are inferred from the claim text.